Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Penicacid V is a novel mycophenolic acid derivative isolated from the marine-derived fungus *Penicillium senticosum* RCDB005, which was discovered in sediment samples from the South China Sea. It is part of a group of secondary metabolites (penicacids O-W) characterized by their structural similarity to mycophenolic acid. In preclinical research, penicacid V has demonstrated significant anti-proliferative activity against human cancer cell lines, specifically showing potent inhibitory effects on the MOLM-13 acute myeloid leukemia (AML) cell line with IC50 values in the low micromolar range. As a mycophenolic acid derivative, its biological activity is likely mediated through the inhibition of inosine-5'-monophosphate dehydrogenase (IMPDH), an enzyme essential for de novo guanosine nucleotide biosynthesis, which is a critical pathway for the proliferation of certain leukemia cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on penicacid V.